Combined Federal Campaign
PHA is #0212 Spread the Word!
Fall has arrived and so has the
2004 Combined Federal Campaign (CFC). Federal and
postal employees as well as military
personnel and retirees can contribute to the Pulmonary Hypertension Association
(PHA) through the Combined Federal Campaign.
When you complete your CFC pledge card,
be sure to write in 0212 so PHA will receive your gift. Your
contribution will be
used to support PHA’s important programs, including research,
education, outreach and patient services.
Not a federal employee? Then help PHA spread the word by forwarding
this email or calling your friends and/or family who can participate
in the Combined Federal Campaign. Let them know how they can
make a difference!
With your help we can meet our goal to raise $40,000.
On behalf of the thousands of
men, women, children and families battling pulmonary hypertension,
we extend many thanks to all
who participated in the 2003 campaign. Last year, CFC
pledges totaled nearly $30,000!
Study Shows Improvements in Six-Minute Walk Distance and NYHA Functional
Class in Patients With Pulmonary Arterial Hypertension Related
to Connective Tissue
Diseases
HOUSTON, Oct. 18 /PRNewswire-FirstCall/ -- Encysive
Pharmaceuticals (Nasdaq: ENCY) today announced that new clinical
data on Thelin(TM)
(sitaxsentan) will be presented at the American College of Rheumatology
(ACR) Annual Scientific Meeting in San Antonio (October 16-21).
Results from a subgroup analysis of the 178-patient pivotal Phase
IIb/III STRIDE-1 (Sitaxsentan To Relieve ImpaireD Exercise) will
be discussed showing the positive impact of Thelin upon patients
with pulmonary arterial hypertension
(PAH) related to connective tissue diseases, such as scleroderma
and lupus, during a scientific session to take place on Thursday,
October 21 at 9 a.m.
Chest 2004 hosts world experts in pulmonary, sleep, and critical
care medicine
Cardiopulmonary, sleep, and critical care experts from around the world
will present the latest research related to clinical chest medicine during
CHEST 2004, the multidisciplinary world congress on diseases of the chest,
held October 23-28, in Seattle, WA.
The annual international scientific assembly of the American College
of Chest Physicians (ACCP) will host 500 national and international experts
and up-and-coming investigators as they present more than 800 cutting-edge
research abstracts and case reports. Thousands of medical professionals
will be on hand to attend more than 150 original scientific sessions,
honor lectures, educational, and satellite symposia, covering a broad
range of subspecialty topics, including sleep medicine, pediatric pulmonology,
disaster medicine, pulmonary vascular disease, lung cancer, chronic obstructive
pulmonary disease (COPD), cardiology, and critical care.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information resource
for people dealing with PH -- they have ARRIVED and are ready to
ship!!!
The author, a PH patient herself,
knows what it is like to live with the disease. She talked to many
other patients, doctors, and researchers while writing the Survival
Guide. Dr. Ronald J. Oudiz and a team of physicians with a deep
knowledge of PH edited the book for accuracy.
New edition contains a chart
of 15 drugs used to treat PH; results of recent
clinical trials;
in-depth discussion of PH secondary to other diseases
or conditions;
a new chapter on what to eat if you have PH; and much, much more!
Actelion
Ltd.: New scientific studies show higher than expected prevalence of
Pulmonary Arterial Hypertension in patients with Connective Tissue
Diseases (CTD
ALLSCHWIL, Swtzerland and SAN ANTONIO, Texas, Oct. 18, 2004 (PRIMEZONE)
-- Actelion Ltd. (PinkSheets:ALIOF): Studies reported at the American
College of Rheumatology (ACR) support early diagnostic intervention --
Echocardiography and confirmatory right heart catheterization as appropriate
tools.
Two new scientific studies released today at the American College of
Rheumatology (ACR) are reporting a high prevalence of both diagnosed
and undiagnosed pulmonary arterial hypertension (PAH) in patients with
scleroderma and mixed connective tissue disease (MCTD).
The two studies -- sponsored by Actelion Ltd. (SWX:ATLN) -- were carried
out in the United States and Europe. They are presented at a joint scientific
poster presentation on Tuesday. On Monday, the official media activities
of the conference organizer will also focus on the important role of
early detection and treatment of PAH especially in these patients at
high risk for developing this rapidly progressing and ultimately fatal
disease (see media advisory at the end of this release).
PHA’s Guide
to Understanding Your Healthcare Insurance Benefits is
now available for review. This guide was developed
to help patients understand health insurance
coverage and to provide the tools to
obtain the most from benefits.
When we only had a Table of Contents,
we received hundreds of invaluable comments. Please
take the time to review this draft Guide and give us your feedback.
Thank you!
CoTherix,
Inc. Announces Initial Public Offering of 5,000,000 Shares of Common
Stock at $6.00 Per Share
SOUTH SAN FRANCISCO, Calif., Oct. 15
/PRNewswire-FirstCall/ -- CoTherix, Inc. (Nasdaq: CTRX) announced today
the initial public offering of 5,000,000 shares of common stock at
$6.00 per share. In addition, CoTherix has granted to the underwriters
a 30-day option to purchase up to 750,000 additional shares to cover
over-allotments, if any. All of the shares are being offered by CoTherix.
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
PHA’s Guide
to Understanding Your Healthcare Insurance Benefits is
now available for review. This guide was developed
to help patients understand health insurance
coverage and to provide the tools to
obtain the most from benefits.
